Search terms
Results 1 - 10 of 65 - ordered by :
Pages: 1 2 3 4 5 6 7 ... 7

Saturday 30 August 2014: A new ESC journal on cardiovascular pharmacotherapy is launched today at ESC Congress by the ESC and Oxford University Press. Editor in chief Professor Stefan Agewall said: ...

Date : 30/08/2014

Munich, Germany – 28 Aug 2018: A new treatment can halve hospital stays for some patients with a heart infection (endocarditis), according to late breaking results of the POET trial (1) ...

Date : 28/08/2018

[...]the differences in diet, physical activity and smoking between wealthy and poor households were less marked among those living in urban areas than those living in rural areas. “Policies to ...

Date : 26/08/2012

Having studied biomedical engineering before my medical degree, I was always interested in the technical aspects of medicine and I became fascinated by pacemakers. [...]it was a welcome, but steep, ...

Date : 19/03/2018

What is your greatest work achievement? I am proud not only of landmark achievements, such as becoming Professor of Cardiology and serving as Head of the Department of Cardiology for more than 10 ...

Date : 18/03/2018

According to the INNOVATE PCI trial, elinogrel provides a more potent antiplatelet effect in both the IV and oral forms; however, this immediate platelet inhibition has yet to be translated into a ...

Date : 30/08/2010

Dal-VESSEL was an exploratory phase IIb randomised, double-blind, placebo-controlled trial in patients with coronary heart disease (CHD), or CHD risk equivalents, in which 476 patients with HDL-C ...

Date : 28/08/2011

Thrombus aspiration before percutaneous coronary intervention (PCI) does not improve 12-month clinical outcomes in patients with non-ST-elevation myocardial infarction (NSTEMI), according to results ...

Date : 19/11/2015

Myocardial injury, major bleeding, and sepsis contributed to nearly three-quarters of all deaths. “There’s a false assumption among patients that once you’ve undergone surgery, ...

Date : 27/08/2018

Results of the Phase III EINSTEIN-DVT study show that the oral anticoagulant rivaroxaban achieved the primary efficacy and safety outcomes in the treatment of patients with acute, symptomatic deep ...

Date : 31/08/2010